NCT03245385 - Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2017

Primary Completion Date

February 5, 2018

Study Completion Date

February 5, 2018

Conditions

Atopic Dermatitis

Interventions

DRUG

Treatment with Halobetasol propionate 0.05% topical spray

Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g

Trial Locations (13)

18201

L&C Professional Medical Research Institute, Hazleton

32256

Solutions Through Advanced Research, Jacksonville

33015

Integrity Research Center, Miami

33016

Vital Pharma Research, Hialeah

33125

Millennium Clinical Research, INC, Miami

33155

Regenerate Clinical Trials, LLC, Miami

33166

Life Medical Center and Research, INC, Miami

33176

Vista Health Research, Miami

48085

Elias Research, Troy

49808

Montana Medical Research/Elias Research Assoc., Missoula

78215

Sun Research Institute, San Antonio

91105

Havana Research Institute, Pasadena

91606

Providence Clinical Research, North Hollywood